Palvella Therapeutics, Inc. Increase (Decrease) in Restricted Cash
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Restricted Cash of -$70.03 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2016-03-23
- Palvella Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2014-12-31 was -$57.05K.
- Palvella Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2014-09-30 was $118.00.
- Palvella Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2014-06-30 was -$12.18K.
- Palvella Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2014-03-31 was -$911.00.
- Palvella Therapeutics, Inc. increase (decrease) in restricted cash for fiscal 2014 was -$70.03K.
- Palvella Therapeutics, Inc. increase (decrease) in restricted cash for fiscal 2013 was -$114.26K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2014-12-31 | -$57.05K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -$56.94K derived: sum of 2 quarters · filed 2016-03-23 | -$69.11K derived: sum of 3 quarters · filed 2016-03-23 | -$70.03K 10-K · filed 2016-03-23 |
| 2014-09-30 | $118.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$12.06K derived: sum of 2 quarters · filed 2015-11-13 | -$12.97K 10-Q · filed 2015-11-13 | |
| 2014-06-30 | -$12.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$13.09K 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | -$911.00 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | -$114.26K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |